<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248104</url>
  </required_header>
  <id_info>
    <org_study_id>5100064</org_study_id>
    <nct_id>NCT01248104</nct_id>
  </id_info>
  <brief_title>Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery</brief_title>
  <official_title>Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We designed a prospective double-blinded randomized trial in an attempt to detect a&#xD;
      difference between tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) in reducing&#xD;
      transfusion in patients undergoing cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: This study compares the efficacy of tranexamic acid (TXA) to epsilon aminocaproic&#xD;
      acid (EACA) in reducing blood loss in patients undergoing cardiac surgery. Methods: This was&#xD;
      a double-blinded randomized trial. Patients (n=100) undergoing cardi- ac surgery were&#xD;
      randomized to receive either TXA (10 mg/kg bolus followed by an infu- sion of 1mg/kg/hr) or&#xD;
      EACA (150mg/kg bolus followed by an infusion of 20 mg/kg/hr). The primary outcome measure was&#xD;
      a difference in transfusion amounts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Transfusion Amounts</measure>
    <time_frame>48 hours</time_frame>
    <description>The outcome measure was the intergroup difference in total transfusion amounts up to post-operative day 2.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The TXA group re- ceived a bolus of 10 mg / kg over 15 minutes fol- lowed by an infusion of 1 mg/kg/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aminocaproic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The EACA group received a bolus of 100 mg / kg given over 15 minutes shortly after induction of anesthesia followed by an infusion of 10 mg/kg/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Infusion during cardiac surgery</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminocaproic Acid</intervention_name>
    <description>Infusion during cardiac surgery</description>
    <arm_group_label>Aminocaproic Acid</arm_group_label>
    <other_name>Amicar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is the subject 18 years of age or older?&#xD;
&#xD;
          2. Is the subject scheduled for primary cardiac surgery utilizing cardiopulmonary&#xD;
             bypass(CPB)?&#xD;
&#xD;
          3. Is the subject more than 30 kg ( 66 lbs)?&#xD;
&#xD;
          4. Does subject understand English?&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Does the subject have existing coagulation defects (INR &gt; 1.5, platelets &lt; 100 ?&#xD;
&#xD;
          2. Does the subject have renal failure (defined as BUN/Cr ratio 20:1 ?&#xD;
&#xD;
          3. Does the subject have severe liver disease (AST &amp; ALT&gt; 3x normal) ?&#xD;
&#xD;
          4. Is the subject having emergency cardiac surgery, complex aortic surgery, combination&#xD;
             valve/CABG surgeries, or redo cardiac surgery?&#xD;
&#xD;
          5. Is the subject having any procedure where CPB is not anticipated?&#xD;
&#xD;
          6. Is the patient weight greater than 150 kg?&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Gatling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 15, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <results_first_submitted>October 11, 2016</results_first_submitted>
  <results_first_submitted_qc>August 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2020</results_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Jason Gatling, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Cardiac Surgery</keyword>
  <keyword>Antifibrinolytic agents</keyword>
  <keyword>Blood transfusion</keyword>
  <keyword>epsilon aminocaproic acid</keyword>
  <keyword>tranexamic acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Aminocaproic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult patients scheduled for primary cardiac surgery utilizing CPB at LLUMC . Subjects myst be &gt;30 kg, be able to understand English, and sign the consent form.Subjects will be recruited in the pre-admitting area prior to going to the PDCU area in the operating room.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tranexamic Acid</title>
          <description>Tranexamic Acid: Infusion during cardiac surgery</description>
        </group>
        <group group_id="P2">
          <title>Aminocaproic Acid</title>
          <description>Aminocaproic Acid: Infusion during cardiac surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tranexamic Acid</title>
          <description>Tranexamic Acid: Infusion during cardiac surgery</description>
        </group>
        <group group_id="B2">
          <title>Aminocaproic Acid</title>
          <description>Aminocaproic Acid: Infusion during cardiac surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.79175" spread="13.1260508"/>
                    <measurement group_id="B2" value="63.25333" spread="12.62622"/>
                    <measurement group_id="B3" value="63.51597561" spread="12.79547179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Transfusion Amounts</title>
        <description>The outcome measure was the intergroup difference in total transfusion amounts up to post-operative day 2.</description>
        <time_frame>48 hours</time_frame>
        <population>equality in both arms</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Tranexamic Acid: Infusion during cardiac surgery</description>
          </group>
          <group group_id="O2">
            <title>Aminocaproic Acid</title>
            <description>Aminocaproic Acid: Infusion during cardiac surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Total Transfusion Amounts</title>
          <description>The outcome measure was the intergroup difference in total transfusion amounts up to post-operative day 2.</description>
          <population>equality in both arms</population>
          <units>mililiters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161" spread="274"/>
                    <measurement group_id="O2" value="116" spread="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A power analysis based on the comparison of a 15% difference in total transfusion amounts up to POD 2 between the treatment groups indicated a total sample size of 80 with a power of 0.8, confidence interval 0.9, and p= 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Continuous variables were compared by multivariate linear regression analysis to adjust for possible covariates of intraoperative fluids, age, bypass time, and procedure time. Tukey-Kramer test was then used to compare for specific differences between groups for each variable. Categorical data were compared using Fisher's exact test. All comparisons were made at a significance level of 0.05, and analysis was performed with Minitab version 17).</non_inferiority_desc>
            <p_value>0.35</p_value>
            <p_value_desc>The primary outcome measure showed that there was no difference in PRBC transfusion frequency or amounts in the operating room or the in ICU up to POD 2</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>length of hospital admission, an average of 5 days</time_frame>
      <desc>adverse events were recorded via review of electronic medical record</desc>
      <group_list>
        <group group_id="E1">
          <title>Tranexamic Acid</title>
          <description>Tranexamic Acid: Infusion during cardiac surgery</description>
        </group>
        <group group_id="E2">
          <title>Aminocaproic Acid</title>
          <description>Aminocaproic Acid: Infusion during cardiac surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jason Gatling</name_or_title>
      <organization>Loma Linda University Medical Center</organization>
      <phone>909-558-4475 ext 44475</phone>
      <email>jgatling@llu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

